Allosteric Inhibitors Targeting PIK3CA May Reduce Treatment Toxicities in Breast Cancer
A few allosteric inhibitors have arrived that have been developed to reduce toxicities with mutation-specific targeting and build upon the efficacy seen with orthosteric inhibitors such as alpelisib (Piqray) and the recently approved inavolisib (Itovebi) …